Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Maughan

Showing results (91-100 of 111) with videos related to

Pageof 12
Sort By:
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
The Lancet. Oncology|June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
Journal for Immunotherapy of Cancer|March 18, 2025
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)Gliceida M Galarza Fortuna, Daniel Grass, Benjamin L Maughan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2021
Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell CarcinomaZeynep B Zengin, Caroline Weipert, Nicholas J Salgia, et al.
Ophthalmology|February 22, 2025
CorrigendumHenry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
The Prostate|April 1, 2024
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive settingGeorges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, et al.
Ophthalmology|June 7, 2024
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 StudyHenry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
Clinical Proteomics|April 18, 2025
Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancerHyejung Lee, Jincheng Shen, Muhammad Zaki Fadlullah, et al.
The Oncologist|August 29, 2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on RaceRaquel Zimmerman, Mehmet A Bilen, Elisabeth I Heath, et al.
Pageof 12

Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
The Lancet. Oncology|June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
Journal for Immunotherapy of Cancer|March 18, 2025
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)Gliceida M Galarza Fortuna, Daniel Grass, Benjamin L Maughan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2021
Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell CarcinomaZeynep B Zengin, Caroline Weipert, Nicholas J Salgia, et al.
Ophthalmology|February 22, 2025
CorrigendumHenry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
The Prostate|April 1, 2024
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive settingGeorges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, et al.
Ophthalmology|June 7, 2024
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 StudyHenry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
Clinical Proteomics|April 18, 2025
Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancerHyejung Lee, Jincheng Shen, Muhammad Zaki Fadlullah, et al.
The Oncologist|August 29, 2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on RaceRaquel Zimmerman, Mehmet A Bilen, Elisabeth I Heath, et al.
Pageof 12